Literature DB >> 3025604

Comparison of the trans-activation capabilities of the human T-cell leukemia virus type I and II chi proteins.

N P Shah, W Wachsman, A J Cann, L Souza, D J Slamon, I S Chen.   

Abstract

The mechanism of cellular transformation by the human T-cell leukemia viruses (HTLVs) is thought to involve a novel retrovirus gene known as chi. The chi gene is essential for HTLV replication and acts by enhancing transcription from the viral long terminal repeat. By using the HTLV type I and II chi gene-coding regions inserted into a highly efficient expression vector, we directly compared the efficiencies of the two chi proteins to trans activate the HTLV type I and II long terminal repeats. We demonstrate that the two chi proteins have different patterns of trans activation. The patterns were highly reproducible in all mammalian cells tested. A different pattern of activation was observed in avian cells. These results suggest that the mechanism of trans activation involves specific cellular factors that are highly conserved throughout mammalian species but different in avian cells. Understanding the mechanism of trans activation by the chi gene product may provide insights into mechanisms of cellular transformation by HTLV.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3025604      PMCID: PMC367123          DOI: 10.1128/mcb.6.11.3626-3631.1986

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  37 in total

1.  INFECTION OF HUMAN AND SIMIAN TISSUE CULTURES WITH ROUS SARCOMA VIRUS.

Authors:  F C JENSEN; A J GIRARDI; R V GILDEN; H KOPROWSKI
Journal:  Proc Natl Acad Sci U S A       Date:  1964-07       Impact factor: 11.205

2.  A partially purified polypeptide fraction from rat liver cell conditioned medium with multiplication-stimulating activity for embryo fibroblasts.

Authors:  N C Dulak; H M Temin
Journal:  J Cell Physiol       Date:  1973-04       Impact factor: 6.384

3.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells.

Authors:  I Miyoshi; I Kubonishi; S Yoshimoto; T Akagi; Y Ohtsuki; Y Shiraishi; K Nagata; Y Hinuma
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

4.  SV40-transformed simian cells support the replication of early SV40 mutants.

Authors:  Y Gluzman
Journal:  Cell       Date:  1981-01       Impact factor: 41.582

5.  Partial transformation of primary rat cells by the leftmost 4.5% fragment of adenovirus 5 DNA.

Authors:  A Houweling; P J van den Elsen; A J van der Eb
Journal:  Virology       Date:  1980-09       Impact factor: 3.616

6.  Pre-early adenovirus 5 gene product regulates synthesis of early viral messenger RNAs.

Authors:  A J Berk; F Lee; T Harrison; J Williams; P A Sharp
Journal:  Cell       Date:  1979-08       Impact factor: 41.582

7.  Continuous tissue culture cell lines derived from chemically induced tumors of Japanese quail.

Authors:  C Moscovici; M G Moscovici; H Jimenez; M M Lai; M J Hayman; P K Vogt
Journal:  Cell       Date:  1977-05       Impact factor: 41.582

8.  Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells.

Authors:  J L Jainchill; S A Aaronson; G J Todaro
Journal:  J Virol       Date:  1969-11       Impact factor: 5.103

9.  Expression of early adenovirus genes requires a viral encoded acidic polypeptide.

Authors:  R P Ricciardi; R L Jones; C L Cepko; P A Sharp; B E Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

10.  Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera.

Authors:  Y Hinuma; K Nagata; M Hanaoka; M Nakai; T Matsumoto; K I Kinoshita; S Shirakawa; I Miyoshi
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

View more
  12 in total

Review 1.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

2.  Studies of heterologous promoter trans-activation by the HTLV-II tax protein.

Authors:  J L Williams; A J Cann; T Leff; P Sassone-Corsi; I S Chen
Journal:  Nucleic Acids Res       Date:  1989-07-25       Impact factor: 16.971

3.  Protein kinase A-dependent binding of a nuclear factor to the 21-base-pair repeat of the human T-cell leukemia virus type I long terminal repeat.

Authors:  H T Poteat; F Y Chen; P Kadison; J G Sodroski; W A Haseltine
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

Review 4.  The origin and evolution of human T-cell lymphotropic virus types I and II.

Authors:  Y Suzuki; T Gojobori
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

5.  In vitro mutagenesis of the human T-cell leukemia virus types I and II tax genes.

Authors:  A J Cann; J D Rosenblatt; W Wachsman; I S Chen
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

6.  Regulation of expression of the c-sis proto-oncogene.

Authors:  L Ratner
Journal:  Nucleic Acids Res       Date:  1989-06-12       Impact factor: 16.971

7.  Differential transactivation of the intercellular adhesion molecule 1 gene promoter by Tax1 and Tax2 of human T-cell leukemia viruses.

Authors:  Y Tanaka; M Hayashi; S Takagi; O Yoshie
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

8.  cis-acting regulatory regions in the long terminal repeat of simian foamy virus type 1.

Authors:  A Mergia; E Pratt-Lowe; K E Shaw; L W Renshaw-Gegg; P A Luciw
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

9.  Tax and overlapping rex sequences do not confer the distinct transformation tropisms of human T-cell leukemia virus types 1 and 2.

Authors:  Jianxin Ye; Li Xie; Patrick L Green
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

10.  Human T-cell leukemia virus types I and II exhibit different DNase I protection patterns.

Authors:  R Altman; D Harrich; J A Garcia; R B Gaynor
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.